Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.8% – What’s Next?

Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) rose 0.8% on Thursday . The company traded as high as $2.65 and last traded at $2.65. Approximately 1,219,900 shares changed hands during mid-day trading, an increase of 29% from the average daily volume of 947,968 shares. The stock had previously closed at $2.63.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. HC Wainwright dropped their target price on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Repare Therapeutics in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. Finally, TD Cowen downgraded shares of Repare Therapeutics to a “hold” rating in a research report on Monday, November 17th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Repare Therapeutics presently has an average rating of “Hold” and a consensus target price of $3.00.

Repare Therapeutics Stock Performance

The firm’s 50 day moving average is $2.55 and its 200-day moving average is $2.07. The stock has a market capitalization of $114.24 million, a price-to-earnings ratio of -1.57 and a beta of 0.97.

Hedge Funds Weigh In On Repare Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP purchased a new position in Repare Therapeutics in the 4th quarter valued at about $2,901,000. Renaissance Technologies LLC lifted its position in shares of Repare Therapeutics by 35.5% in the fourth quarter. Renaissance Technologies LLC now owns 981,360 shares of the company’s stock valued at $2,552,000 after acquiring an additional 257,200 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Repare Therapeutics by 35.6% in the first quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after acquiring an additional 168,230 shares during the last quarter. Rangeley Capital LLC purchased a new stake in shares of Repare Therapeutics during the second quarter worth approximately $494,000. Finally, Yakira Capital Management Inc. acquired a new position in Repare Therapeutics in the 4th quarter valued at $693,000. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.